Avay Biosciences
Avay Biosciences is developing advanced bio 3D printers, notably the ‘Mito Plus’, which can print human tissues for research, drug testing, and potential organ creation.
- CEO / Founder
- Manish Amin
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $288K
- Latest Round
- Seed
- Key Investors
- Biotechnology Industry Research Assistance Council (BIRAC), Startup India
Technology & Products
Key Products
["Mito Plus 3D Bioprinter","3D-printed liver cell models","Printed skin tissue models"]
Technological Advantage
Strong academic and research collaborations with premier national institutions coupled with patent-pending bio 3D printing technology.
Differentiation
Value Proposition
Indigenous, end-to-end bio 3D printing solutions enabling custom tissue creation to enhance drug testing outcomes and reduce organ transplant rejection risks.
How They Differentiate
Focused on fully indigenous development to produce functional tissues/organs with strong academic backing and integrated advanced features.
Market & Competition
Target Customers
Medical research institutions, healthcare organizations, and pharmaceutical companies
Industry Verticals
["Healthcare","Medical Research","Pharmaceutical"]
Competitors
Pandorum Technologies; Organovo
Growth & Milestones
Growth Metrics
Not disclosed
Major Milestones
["Launched the 'Mito Plus' bioprinter at Bengaluru Tech Summit (November 2022)","Successfully printed liver cell models for drug testing","Established collaborations with top national research institutions"]
Notable Customers
IIT Madras; IISc Bangalore; Institute of Chemical Technology (ICT), Mumbai; NIPER, Hyderabad; BITS Pilani (Goa Campus)